Treatment of diabetic neuropathy with a novel PAR1-targeting molecule

Efrat Shavit-Stein*, Shany Guly Gofrit, Alexandra Gayster, Yotam Teldan, Ariel Ron, Eiman Abu Bandora, Valery Golderman, Orna Gera, Sagi Harnof, Joab Chapman, Amir Dori

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Diabetic peripheral neuropathy (DPN) is a disabling common complication of diabetes mellitus (DM). Thrombin, a coagulation factor, is increased in DM and affects nerve function via its G-protein coupled protease activated receptor 1 (PAR1). Methods: A novel PAR1 modulator (PARIN5) was designed based on the thrombin PAR1 recognition site. Coagulation, motor and sensory function and small fiber loss were evaluated by employing the murine streptozotocin diabetes model. Results: PARIN5 showed a safe coagulation profile and showed no significant effect on weight or glucose levels. Diabetic mice spent shorter time on the rotarod (p <0.001), and had hypoalgesia (p <0.05), slow conduction velocity (p <0.0001) and reduced skin innervation (p <0.0001). Treatment with PARIN5 significantly improved rotarod performance (p <0.05), normalized hypoalgesia (p <0.05), attenuated slowing of nerve conduction velocity (p <0.05) and improved skin innervation (p <0.0001). Conclusion: PARIN5 is a novel pharmacological approach for prevention of DPN development, via PAR1 pathway modulation.

Original languageEnglish
Article number1552
Pages (from-to)1-11
Number of pages11
Issue number11
StatePublished - Nov 2020


  • Diabetes mellitus
  • PAR1
  • Peripheral neuropathy
  • Streptozotocin
  • Thrombin


Dive into the research topics of 'Treatment of diabetic neuropathy with a novel PAR1-targeting molecule'. Together they form a unique fingerprint.

Cite this